Shipping
Same-day shipping on USA orders placed before 2PM EST.
View Shipping Policy →
99%+ Purity Guaranteed
Research Use Only
Secure Checkout
IGF-1 LR3 1mg
SKU: IGFLR31M
Same Trusted Formula. Fresh New Look.During our packaging transition, you may receive products with either our previous or updated label. Rest assured, the formulation, purity and quality remain exactly the same as per our standards.
Accepted Payment MethodsYour data is protected with 256-bit encryption.
Returns
30-day hassle-free returns on unopened products.
View Returns Policy →Lab Tested
Every batch is tested for purity, potency and quality.
View Lab Results →Support
Have a question? Our team is here to help you.
Contact Us →IGF-1 LR3 (Long Arg3-IGF-1) is a synthetic 83-amino-acid analogue of insulin-like growth factor 1, engineered with an N-terminal 13-amino-acid extension and an Arg3 substitution that together confer markedly reduced affinity for IGF-binding proteins (IGFBPs) and extended plasma half-life. These modifications preserve IGF-1 receptor (IGF-1R) agonist activity while reducing IGFBP sequestration, enabling sustained receptor engagement in preclinical research models.
- High Purity — 99%+ Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
All SwissChems products are independently third-party tested at a USA-based HPLC-licensed laboratory prior to distribution. Certificates of Analysis (COA) are published on the Independent Test Results page and available at product level. If any independently conducted HPLC test returns a negative result, SwissChems will refund: (1) the cost of the HPLC test, and (2) the full order amount including shipping.
| Chemical Formula | C400H625N111O115S9 |
|---|---|
| Synonyms | Long R3-IGF-1, M9L22Y19H9, 143045-27-6, Long-(arg3)insulin-like growth factor-i |
| Molar Mass | 9,117.60 g/mol |
| CAS Number | 143045-27-6 |
| PubChem CID | N/A |
| Total Compound Content | 1 mg per vial |
| Shelf Life | 36 months |
IGF-1 LR3 is a recombinant 83-amino-acid analogue of native IGF-1 (70 AA) featuring two structural modifications: an N-terminal 13-residue extension (MFPAMPLLSLFVN) and substitution of glutamic acid at position 3 with arginine (Arg3). These changes reduce IGFBP-1 through IGFBP-6 binding affinity by approximately 1,000-fold relative to native IGF-1, effectively eliminating IGFBP sequestration and increasing the proportion of free, biologically active peptide in experimental systems. Full IGF-1R agonist activity is preserved, with downstream activation of PI3K/Akt, MAPK/ERK, and mTOR signalling cascades. Plasma half-life extends to approximately 56–72 hours versus approximately 10–20 minutes for native IGF-1. Researchers use IGF-1 LR3 to investigate IGF-1R signalling in sustained-activation contexts, anabolic pathway regulation, and the consequences of IGFBP-uncoupled IGF-1R engagement on cell proliferation, differentiation, and metabolic substrate utilisation. Supplied as lyophilised preparation (1 mg/vial). Independently third-party HPLC-tested; COA available per batch.
IGF-1 LR3 (HPLC)
April 28, 2026
Why does IGF-1 LR3 have a longer half-life than native IGF-1?
Native IGF-1 is rapidly sequestered in circulation by IGF-binding proteins (IGFBPs 1–6), which extend its half-life but also restrict bioavailability. The Arg3 substitution and N-terminal 13-residue extension in IGF-1 LR3 reduce IGFBP affinity by approximately 1,000-fold, preventing this sequestration. Without IGFBP binding, IGF-1 LR3 remains in free, receptor-accessible form for 56–72 hours — substantially longer than native IGF-1's 10–20-minute half-life when not IGFBP-bound.
Which intracellular signalling pathways does IGF-1 LR3 activate via IGF-1R?
IGF-1R is a receptor tyrosine kinase. Ligand binding drives receptor autophosphorylation, IRS-1/IRS-2 adapter recruitment, and activation of two primary downstream cascades: PI3K/Akt/mTOR (governing protein synthesis, glucose uptake, and cell survival) and MAPK/ERK (regulating cell proliferation and differentiation). Both pathways are fully engaged by IGF-1 LR3 at the IGF-1R, identical to native IGF-1.
What types of experimental programs are most suited to the IGF-1 LR3 10-vial KIT format?
The IGF-1 LR3 KIT format is particularly useful for longitudinal investigations, multi-arm experimental designs, concentration-response studies, receptor-signaling experiments, and pathway-characterization programs that require repeated compound preparation over extended periods. The availability of multiple matched-batch vials supports consistent experimental conditions across separate study phases, treatment groups, and sampling timepoints. This makes the KIT format well-suited to research involving IGF-1 receptor signaling, PI3K/Akt/mTOR pathway analysis, MAPK/ERK pathway investigation, and comparative insulin-like growth factor pharmacology.
